Huang, Y; Gu, B; Salles-Crawley, II; Taylor, KA; Yu, L; Ren, J; Liu, X; ... Chen, R; + view all Huang, Y; Gu, B; Salles-Crawley, II; Taylor, KA; Yu, L; Ren, J; Liu, X; Emerson, M; Longstaff, C; Hughes, AD; Thom, SA; Xu, XY; Chen, R; - view fewer (2021) Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy. Science Advances , 7 (23) 10.1126/sciadv.abf9033.

Preview

Text eabf9033.full.pdf - Published Version Download (8MB) | Preview

Abstract

Clinical use of tissue plasminogen activator (tPA) in thrombolytic therapy is limited by its short circulation time and hemorrhagic side effects. Inspired by fibrinogen binding to activated platelets, we report a fibrinogen-mimicking, multiarm nanovesicle for thrombus-specific tPA delivery and targeted thrombolysis. This biomimetic system is based on the lipid nanovesicle coated with polyethylene glycol (PEG) terminally conjugated with a cyclic RGD (cRGD) peptide. Our experiments with human blood demonstrated its highly selective binding to activated platelets and efficient tPA release at a thrombus site under both static and physiological flow conditions. Its clot dissolution time in a microfluidic system was comparable to that of free tPA. Furthermore, we report a purpose-built computational model capable of simulating targeted thrombolysis of the tPA-loaded nanovesicle and with a potential in predicting the dynamics of thrombolysis in physiologically realistic scenarios. This combined experimental and computational work presents a promising platform for development of thrombolytic nanomedicines.

Download activity - last month

Export as JSONCSVXML

Download activity - last 12 months

Export as XMLJSONCSV

Downloads by country - last 12 months

Export as JSONCSVXML

Archive Staff Only

View Item